These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9865328)

  • 41. Severe liver damage with leflunomide.
    Prescrire Int; 2001 Oct; 10(55):149. PubMed ID: 11824431
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Update on immununosuppressive therapies for dogs and cats.
    Viviano KR
    Vet Clin North Am Small Anim Pract; 2013 Sep; 43(5):1149-70. PubMed ID: 23890244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Leflunomide in the treatment of palmoplantar pustulosis.
    Melwani PM; Peñate Y; Guillermo N; Soler E; Hernández-Machín B; Borrego L
    Arch Dermatol; 2009 Nov; 145(11):1224-6. PubMed ID: 19917950
    [No Abstract]   [Full Text] [Related]  

  • 44. Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection.
    Krisl JC; Taber DJ; Pilch N; Chavin K; Bratton C; Thomas B; McGillicuddy J; Baliga P
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):1003-9. PubMed ID: 22461534
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Leflunomide for polyomavirus type BK nephropathy.
    Williams JW; Javaid B; Kadambi PV; Gillen D; Harland R; Thistlewaite JR; Garfinkel M; Foster P; Atwood W; Millis JM; Meehan SM; Josephson MA
    N Engl J Med; 2005 Mar; 352(11):1157-8. PubMed ID: 15784677
    [No Abstract]   [Full Text] [Related]  

  • 46. Vasculitis occurring during leflunomide therapy.
    Holm EA; Balslev E; Jemec GB
    Dermatology; 2001; 203(3):258-9. PubMed ID: 11701983
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.
    Sawamukai N; Saito K; Yamaoka K; Nakayamada S; Ra C; Tanaka Y
    J Immunol; 2007 Nov; 179(10):6479-84. PubMed ID: 17982036
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of Evans' syndrome with human intravenous immunoglobulin and leflunomide in a diabetic dog.
    Bianco D; Hardy RM
    J Am Anim Hosp Assoc; 2009; 45(3):147-50. PubMed ID: 19411652
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Leflunomide-associated progressive multifocal leukoencephalopathy.
    Rahmlow M; Shuster EA; Dominik J; Deen HG; Dickson DW; Aksamit AJ; Robles HA; Freeman WD
    Arch Neurol; 2008 Nov; 65(11):1538-9. PubMed ID: 19001176
    [No Abstract]   [Full Text] [Related]  

  • 50. Is leflunomide effective in the treatment of psoriasis in a patient who is unable to benefit from standard first- and second-line therapies and needs an affordable treatment option?
    Affleck AG; Williams H
    Arch Dermatol; 2008 Dec; 144(12):1642-3. PubMed ID: 19075151
    [No Abstract]   [Full Text] [Related]  

  • 51. Immunosuppression with a combination of the leflunomide analog, FK778, and microemulsified cyclosporine for renal transplantation in mongrel dogs.
    Kyles AE; Gregory CR; Griffey SM; Bernsteen L; Pierce J; Lilja HS; Morris RE
    Transplantation; 2003 Apr; 75(8):1128-33. PubMed ID: 12717190
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune-Mediated Central Nervous System Disease-Current Knowledge and Recommendations.
    Vitale S; Foss K
    Top Companion Anim Med; 2019 Mar; 34():22-29. PubMed ID: 30808493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child.
    Brent RL
    Teratology; 2001 Feb; 63(2):106-12. PubMed ID: 11241434
    [No Abstract]   [Full Text] [Related]  

  • 54. Successful treatment of a leg ulcer occurring in a rheumatoid arthritis patient under leflunomide therapy.
    Knab J; Goos M; Dissemond J
    J Eur Acad Dermatol Venereol; 2005 Mar; 19(2):243-6. PubMed ID: 15752303
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.
    Manna SK; Aggarwal BB
    J Immunol; 1999 Feb; 162(4):2095-102. PubMed ID: 9973483
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An evaluation of leflunomide in the canine renal transplantation model.
    McChesney LP; Xiao F; Sankary HN; Foster PF; Sharma S; Haklin M; Williams JW
    Transplantation; 1994 Jun; 57(12):1717-22. PubMed ID: 8016874
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modulation of human peripheral blood mononuclear cell activation by the combination of leflunomide and pentoxifylline.
    Stojic Vukanic Z; Dimitrijevic M; Colic M; Popovic P; Jandric D
    Transplant Proc; 2001 May; 33(3):2137-8. PubMed ID: 11377478
    [No Abstract]   [Full Text] [Related]  

  • 58. Successful treatment of sarcoidosis with leflunomide.
    Majithia V; Sanders S; Harisdangkul V; Wilson JG
    Rheumatology (Oxford); 2003 May; 42(5):700-2. PubMed ID: 12709556
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment of Felty's syndrome with leflunomide.
    Talip F; Walker N; Khan W; Zimmermann B
    J Rheumatol; 2001 Apr; 28(4):868-70. PubMed ID: 11327265
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study.
    de Souza AW; da Silva MD; Machado LS; Oliveira AC; Pinheiro FA; Sato EI
    Scand J Rheumatol; 2012 May; 41(3):227-30. PubMed ID: 22400913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.